PANBELA THERAPEUTICS, INC.
WACONIA, MN

Sun BioPharma Inc. is a next-generation biopharmaceutical company developing disruptive therapeutics for serious unmet medical needs. The company’s initial programs are aimed at diseases of the pancreas, including pancreatic cancer and pancreatitis. Sun BioPharma has scientific collaborations with pancreatic disease experts at Honor Health in Scottsdale, AZ, Cedars Sinai Medical Center in Los Angeles, the University of Minnesota, Mayo Clinic Scottsdale, the Austin Health Cancer Trials Centre and the Ashford Cancer Centre in Adelaide, Australia. The Company believes that SBP-101 will have a distinct advantage over current pancreatic cancer* therapies in that it specifically targets the exocrine pancreas and can cause ablation, or pharmaceutical resection, of the acinar cells, as well as the primary and metastatic pancreatic cancer, while leaving the insulin-producing islet cells and most non-pancreatic tissue unharmed. Most current cancer therapies (including chemotherapy, radiation or surgery) are associated with significant side effects that further reduce the patient’s quality of life.